Verona Pharma (VRP)
VRP Share PerformanceMore
|52 week high||210.00 24/10/16|
|52 week low||120.75 17/02/17|
|52 week change||-29.50 (-17.35%)|
|4 week volume||571,481 03/03/17|
Media for (VRP)
Latest News« previous» nextMore
22/03/2017 - 08:42 StockMarketWire
Verona Pharma has entered into a global strategic services agreement with QuintilesIMS, a provider of biopharmaceutical...
22/03/2017 - 08:00 RNS
RNS Number: 1503A Verona Pharma PLC 22 March 2017 Verona Pharma Enters Global Strategic Clinical Development Services Agreement with QuintilesIMS for RPL554 Establishes research and operational platform for clinical trials covering COPD and Cystic Fibrosis 22 March 2017, London - Verona Pharma plc (AIM: VRP.L) ( Verona Pharma ), a clinical-stage...
20/03/2017 - 15:00 StockMarketWire
Verona Pharma has confirmed that the Annual General Meeting of the Company will be held on 12th April 2017. At 2:00p...
20/03/2017 - 14:55 RNS
RNS Number: 9721Z Verona Pharma PLC 20 March 2017 Verona Pharma plc ("Verona Pharma" or the "Company") 2016 Annual Report and Accounts and Notice of AGM 20 March 2017, London - Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment o...
02/03/2017 - 14:30 StockMarketWire
Dr Jan-Anders Karlsson, Chief Executive Officer, bought 19,750 shares in the company on the 28th February 2017 at a pric...
02/03/2017 - 10:36 RNS
RNS Number: 3484Y Verona Pharma PLC 02 March 2017 Verona Pharma plc PDMR Dealing 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Dr. Jan-Anders Karlsson 2 Reason for the notification a) Position/status Chief Executive Officer b) Initial notification/Amendment Initial notification 3 Details of the issuer, em...
27/02/2017 - 10:45 StockMarketWire
Verona Pharma has narrowed its FY pretax loss to 5.97m, from a year-ago restated loss of 9.0m. Most of the losses were link...
27/02/2017 - 08:00 RNS
RNS Number: 8595X Verona Pharma PLC 27 February 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. Verona Pharma plc ("Verona Pharma" or the "Company") Financial results for the year ended31 December 2016 27 February 2017,London - Verona Pharma pl...
|Dividend yield||0 %|
Equity Research (VRP)
Verona Pharma plc
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
Verona Pharma plc
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
Verona Pharma plc
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...
- 1 of 2
Latest discussion posts More
“I wonder if there will be any info or timeline for progressing USA FDA approvals to the AGM?”▼
“Agenda here together with resolutions to be voted on http://www.veronapharma.com/uploads/downloads/ver5-2-agm-notice-12-april-2017-final-1490015995.pdf i believe some ...”▼
“here http://www.quintiles.com/ well worth a review of their website and listen to cabell on emerging biopharma - home page other notable ...”▼
Codes & Symbols
|Symbols||VRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP|